Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chungpa-jun (also known as Cheongpajeon) is a traditional Korean herbal decoction developed by Jaseng Hospital of Korean Medicine. It is a core component of an integrative non-surgical treatment package designed for spinal disorders, specifically studied for failed back surgery syndrome (FBSS). The formulation is a multi-herb decoction typically containing 10 to 12 medicinal herbs, including *Ostericum koreanum*, *Eucommia ulmoides*, *Acanthopanax sessiliflorus*, and *Achyranthes bidentata*. These ingredients are selected for their synergistic anti-inflammatory, analgesic, and neuroprotective properties, aiming to reduce pain and improve functional recovery in patients who have not found relief from conventional spinal surgery. In clinical practice and research, it is often administered orally as a 120ml dose twice daily, frequently in conjunction with Chuna manual therapy, acupuncture, and bee venom pharmacopuncture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chungpa-jun.